Test Directory

Test Code
1543
Test Name
Multiple Exostoses NGS Panel
CPT Codes
81479
Expected Turnaround Time
Typically 2 to 4 weeks from receipt of a sample in the laboratory. All cases involving ongoing pregnancies will be expedited.
Clinical Utility
Genetic analysis to provide a molecular diagnosis of this disorder. Recommended for individuals with a personal and/or family history of this disorder to ensure appropriate treatment and establish recurrence risk for family members.
Specimen and Container Info

Non-Prenatal Specimens

Preferred/Alternate

Specimen Type

Containers

Volume

Preferred Specimen Type

Whole Blood

Lavender Top (EDTA)

3 mL

Alternate Specimen Type

Genomic DNA

1.5 mL Tube

3 µg (at a concentration of at least 30 ng/µl), preferably in TE solution.

Alternate Specimen Type

Fibroblasts

T-25 Flasks

2 confluent T-25 flasks, filled to capacity

Alternate Specimen Type

Saliva (Whole blood is recommended for CNV)

DNA Self-Collection Kit or Oragene Saliva Collection Kit for Young Children

Follow kit instructions (www.dnagenotek.com)

Prenatal Specimens

Either specimen type below is acceptable.

Specimen Type

Containers

Volume

Cultured cells

T-25 Flasks

2 confluent T-25 flasks derived from amnio or CVS samples.

Genomic DNA

1.5 mL Tube

3 µg (at a concentration of at least 30 ng/µl), preferably in TE solution.

NOTE: For specimens from outside of North America, the preferred specimen type is Genomic DNA. HNL Genomics does not recommend shipping whole blood or cultured cells from any location other than the United States, Canada, or Mexico.

Transport Instructions
  • Transport at room temperature within 24 hours.
  • If the specimen cannot be transported to the lab within 24 hours, refrigerate for up to 72 hours.
  • Do not freeze or expose to extreme temperatures, refrigerate for up to 72 hours if cannot be transported to lab within 24 hours. 
Stability Requirements

Room Temperature

24 hours

Refrigerated

72 hours

Causes for Rejection
  • Improperly labeled specimen (minimum of two patient identifiers)
  • Inappropriate specimen type
  • Incomplete or incorrect test request form
  • Insufficient volume
  • Specimen has leaked in transit
  • Specimen without a test order
Methodology
Next Generation Sequencing and Copy Number Variation Analysis
Performing Location
Genomics - Snowdrift
Alternate Names
EXT1; EXT2
Description

Exostoses, multiple, type I & II - Multiple exostoses type I (EXT1; MIM 133700) and type II (EXT2; MIM 133701) are autosomal dominant disorders characterized by multiple osteochondromas (MO). Osteochondromas are benign, cartilage-capped bone tumors.  Multiple osteochondromas arise from growth plates and are most numerous in the juxta-epiphyseal region of long tubular bones but also may occur from surfaces of flat bones, vertebrae and ribs.  Complications associated with osteochondromas include compression of nerves, tendons and blood vessels, short stature and deformities of bones leading to functional problems.  Considerable inter- and intrafamilial phenotypic variability is observed in MO.  Chondrosarcomas resulting in malignant transformation of osteochondromas occurs in about 1-5% of patients.  MO is caused by mutations in two genes, exostosin 1 (EXT1) and exostosin 2 (EXT2).  The products of these two genes are involved in the synthesis of heparin sulfate proteoglycans.  EXT1 and EXT2 are also considered to have tumor suppressor gene functions.  In general, a more severe phenotype has been associated with EXT1 mutations.

Deletion of the EXT1 and TRPS1 genes results in trichorhinophalangeal syndrome, type II (TRPS2; MIM 150230).  TRPS2 is also known as Langer-Giedion syndrome (LGS).  TRPS2 is a contiguous gene syndrome with the combined clinical features of trichorhinophalangeal syndrome, type I and multiple exostoses type I.

Testing Schedule
Monday-Friday
Genes
EXT1, EXT2
MIM
133700, 133701
Disease Group
Skeletal Disorders